Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Solid Tumors 2Neoplasms 2Melanoma 2Recurrence 1Pancreatic Adenocarcinoma 1Advanced/Metastatic Solid Tumors 1Adenocarcinoma Pancreas 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Melanoma × selicrelumab × Clear all
NCT01103635 2020-04-07

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
25 enrolled
Dermatologic

Melanoma

NCT01008527 2015-09-24

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
22 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡